Catalysts for Genentech Inc
166 tracked
May 27, 2022
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Feb 28, 2022
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Feb 28, 2022
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Feb 14, 2022
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Feb 2, 2022
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Jan 28, 2022
approval
VABYSMO (FARICIMAB-SVOA) — FDA approval
faricimab
→
Jan 21, 2022
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Oct 22, 2021
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Oct 22, 2021
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Oct 15, 2021
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Oct 6, 2021
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Apr 30, 2021
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Apr 13, 2021
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Mar 4, 2021
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Mar 4, 2021
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Feb 17, 2021
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Feb 17, 2021
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Feb 17, 2021
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Feb 17, 2021
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Feb 17, 2021
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Feb 17, 2021
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Dec 18, 2020
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Dec 18, 2020
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Nov 10, 2020
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Sep 30, 2020
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Sep 27, 2020
approval
KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval
trastuzumab emtansine
→
Sep 18, 2020
approval
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval
polatuzumab vedotin
→
Aug 7, 2020
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Jul 30, 2020
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
May 29, 2020
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→